Navigation Links
Trigemina to Present at the 2013 BIO International Convention
Date:4/22/2013

MORAGA, Calif., April 22, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans , Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, will be presenting at the 2013 BIO International Convention's BIO Business Forum on April 22nd, 2013 at the McCormick Place in Chicago, Illinois.

Dr. Yeomans will be providing an overview of Trigemina's lead product candidate, TI-001, an intranasal oxytocin therapy for the treatment of chronic and subacute head pain, and the therapy's patented mechanism of action as it correlates to its overall safety and efficacy. TI-001, which is being evaluated in a Phase 2 clinical study starting patient enrollment in April 2013, has shown promising preclinical and preliminary study results for use as a safe, non-narcotic form of therapy for the effective relief of chronic migraine.

Event:  BIO International Convention's BIO Business Forum
Date:  Monday, April 22nd, 2013
Place:  Chicago Cubs Room at the McCormick Place
Time:  2:00 pm CT

About Trigemina

Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.

For additional information, please visit www.trigemina.com

About the BIO International Convention

The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit convention.bio.org

Contact:

The Ruth Group
Aaron Estrada (media)
aestrada@theruthgroup.com  
(646) 536-7028

Trigemina
Charles Yeomans
cyeomans@trigemina.com 
(925) 377-0664

 


'/>"/>
SOURCE Trigemina, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
2. Cambridge Semantics to Present the Case for Unified Information Access at Enterprise Data World 2013
3. Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
4. VentriNova, Inc. to present at TEDMED 2013
5. Heptares to Present at Upcoming Scientific and Biotech Industry Conferences
6. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
8. TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
9. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
10. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
11. New Bed Bug Bill Submitted and Complimentary Samples of Non-Pesticide Bed Bug Spray Presented to Help Landlords and Tenants, My Cleaning Products Shares the Details
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... analysis platform specifically designed for life science researchers to analyze and interpret ... Rosalind Franklin, who made a major contribution to the discovery of the ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):